Astria Therapeutics, Inc. (NASDAQ:ATXS – Get Free Report)’s stock price passed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $11.49 and traded as low as $11.07. Astria Therapeutics shares last traded at $11.75, with a volume of 213,048 shares traded.
Analysts Set New Price Targets
Several equities analysts have issued reports on the stock. Wedbush restated an “outperform” rating and issued a $22.00 price objective on shares of Astria Therapeutics in a research note on Tuesday, August 13th. HC Wainwright restated a “buy” rating and set a $16.00 price target on shares of Astria Therapeutics in a research note on Friday, September 27th. Oppenheimer lifted their price target on Astria Therapeutics from $25.00 to $26.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 13th. TD Cowen started coverage on Astria Therapeutics in a report on Monday, July 29th. They issued a “buy” rating and a $35.00 price objective for the company. Finally, Evercore ISI upgraded shares of Astria Therapeutics to a “strong-buy” rating in a research report on Wednesday, August 14th. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $25.20.
Get Our Latest Research Report on ATXS
Astria Therapeutics Trading Up 3.6 %
Astria Therapeutics (NASDAQ:ATXS – Get Free Report) last posted its quarterly earnings data on Monday, August 12th. The biotechnology company reported ($0.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05). Research analysts expect that Astria Therapeutics, Inc. will post -1.72 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently made changes to their positions in ATXS. Vanguard Group Inc. boosted its holdings in Astria Therapeutics by 23.4% in the 1st quarter. Vanguard Group Inc. now owns 2,535,891 shares of the biotechnology company’s stock valued at $35,693,000 after purchasing an additional 480,184 shares in the last quarter. Tidal Investments LLC acquired a new position in Astria Therapeutics during the first quarter worth $1,664,000. Sofinnova Investments Inc. purchased a new position in Astria Therapeutics in the second quarter worth $552,000. ClariVest Asset Management LLC purchased a new position in Astria Therapeutics in the second quarter worth $731,000. Finally, Ameritas Investment Partners Inc. lifted its holdings in Astria Therapeutics by 135.6% in the first quarter. Ameritas Investment Partners Inc. now owns 4,971 shares of the biotechnology company’s stock valued at $70,000 after acquiring an additional 2,861 shares during the period. 98.98% of the stock is currently owned by institutional investors and hedge funds.
Astria Therapeutics Company Profile
Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.
Read More
- Five stocks we like better than Astria Therapeutics
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- What is MarketRankā¢? How to Use it
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- Why Are Stock Sectors Important to Successful Investing?
- Tesla Stock: Buy the Dips, Sell the Rips
Receive News & Ratings for Astria Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astria Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.